Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, and acellular pertussis vaccine, adsorbed
- Development stage
- Unknown
- Lead developer
- Wuhan Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The adsorbed acellular pertussis-diphtheria-tetanus combined vaccine (DTaP) is a trivalent vaccine developed and manufactured by the Wuhan Institute of Biological Products. It is indicated for the active immunization of infants and children against diphtheria, tetanus, and pertussis. The vaccine is formulated by adsorbing purified diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens (typically including pertussis toxoid and filamentous hemagglutinin) onto an aluminum-based adjuvant to enhance immunogenicity. By stimulating the production of specific antibodies, the vaccine provides protection against the toxins produced by *Corynebacterium diphtheriae* and *Clostridium tetani*, as well as the infection caused by *Bordetella pertussis*. It is a standard component of pediatric immunization programs in China.
- Other names
- adsorbed acellular pertussis-diphtheria-tetanus combined vaccine吸附无细胞百白破联合疫苗DTaP vaccineacellular pertussis-diphtheria-tetanus combined vaccine, adsorbed
02
Targets
TCR-DTaP (T-cell receptor specific for diphtheria toxoid, tetanus toxoid, and acellular Bordetella pertussis antigens)Alum (Aluminum phosphate/hydroxide adjuvant surface)TT (Tetanus toxoid)FIM2/3 (Fimbrial protein subunit 2 and 3 (FIM2 and FIM3))PRN (Pertactin autotransporter protein)BCR (Immunoglobulin G B Cell Receptor)FHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on diphtheria, tetanus, and acellular pertussis vaccine, adsorbed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, and acellular pertussis vaccine, adsorbed.